References
- Illah O, Olaitan A. Updates on HPV Vaccination. Diagnostics (Basel). 2023;13(2):243. doi: 10.3390/diagnostics13020243
- Health council of the Netherlands. Vaccination against cervical cancer 2008. Available from: https://www.gezondheidsraad.nl/documenten/adviezen/2008/04/01/vaccinatie-tegen-baarmoederhalskanker
- Schurink T, de Melker H. HPV vaccination: background information for the Dutch Health Council. Rijksinstituut voor Volksgezondheid en Milieu. 2017. https://www.rivm.nl/bibliotheek/rapporten/2017-0020.pdf
- European Medicines Agency. Cervarix. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cervarix
- de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11). doi: 10.1016/S1470-2045(10)70230-8
- Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–527. doi: 10.1056/NEJMoa021641
- Alemany L, Cubilla A, Halec G, et al. Role of human papillomavirus in penile carcinomas worldwide. Eur Urol. 2016;69(5):953–961. doi: 10.1016/j.eururo.2015.12.007
- Alemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136(1):98–107. doi: 10.1002/ijc.28963
- Alemany L, Saunier M, Tinoco L, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer. 2014;50(16):2846–2854. doi: 10.1016/j.ejca.2014.07.018
- Castellsague X, Alemany L, Quer M, et al. HPV involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Cancer Inst. 2016;108:6. doi: 10.1093/jnci/djv403
- de Sanjose S, Alemany L, Ordi J, et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49(16):3450–3461. doi: 10.1016/j.ejca.2013.06.033
- Boot HJ, Wallenburg I, de Melker HE, et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in the Netherlands. Vaccine. 2007;25(33):6245–6256. doi: 10.1016/j.vaccine.2007.05.061
- Drolet M, Benard E, Perez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. The Lancet. 2019;394(10197):497–509. doi: 10.1016/S0140-6736(19)30298-3
- Falcaro M, Castanon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084–2092. doi: 10.1016/S0140-6736(21)02178-4
- Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–527. doi: 10.1093/cid/ciw354
- Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA. 2016;316:22. doi: 10.1001/jama.2016.17615
- Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019;36510. doi: 10.1136/bmj.l1161
- Petaja T, Pedersen C, Poder A, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer. 2011;129(9):2147–2157. doi: 10.1002/ijc.25887
- Bogaards JA, Wallinga J, Brakenhoff RH, et al. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ. 2015;350(may12 7):h2016–h2016. doi: 10.1136/bmj.h2016
- Suijkerbuijk AW, Donken R, Lugner AK, et al. The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases. Expert Rev Vaccines. 2017;16(4):361–375. doi: 10.1080/14760584.2017.1256778
- Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother. 2014;10(7):2109–2111. doi: 10.4161/hv.29137
- Lehtinen M, Apter D. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination. Curr Opin Obstet Gynecol. 2015;27(5):326–332. doi: 10.1097/GCO.0000000000000208
- Morais E, El Mouaddin N, Schuurman S, et al. Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data. Vaccine. 2021;39(39):5461–5473. doi: 10.1016/j.vaccine.2021.08.043
- Spinu AD, Anghel RF, Marcu DR, et al. HPV vaccine for men: where to? (review). Exp Ther Med. 2021;22:5. doi: 10.3892/etm.2021.10701
- Simons JJM, Vida N, Westra TA, et al. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands. Vaccine. 2020;38(30):4687–4694. doi: 10.1016/j.vaccine.2020.05.031
- Simons JJM, Westra TA, Postma MJ. Cost-effectiveness of a male catch-up human papillomavirus vaccination program in the Netherlands. Prev Med Rep. 2022;28:2810. doi: 10.1016/j.pmedr.2022.101872
- Health Council of the Netherlands. Vaccination against HPV. Available from: https://www.healthcouncil.nl/documents/advisory-reports/2019/06/19/vaccination-against-hpv
- National Institute for Public Health and the Environment. More than two million invitations to get vaccinated against HPV in 2023 2023. Available from: https://www.rivm.nl/en/news/more-than-two-million-invitations-to-get-vaccinated-against-hpv-in-2023
- Bruni L, Albero G, Serrano B, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Netherlands. Summary Report. 2023 Mar 10 [cited 2024 Feb 27]. Available from: https://hpvcentre.net/statistics/reports/NLD.pdf
- Staritsky LE, van Aar F, Visser M, et al. Sexually transmitted infections in the Netherlands in 2019. the Netherlands: National Institute for Public Health and the Environment; 2020 [cited 2024 Feb 27]. Available from:https://www.rivm.nl/bibliotheek/rapporten/2020-0052.pdf
- Bruni L, Saura-Lazaro A, Montoliu A, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Prev Med. 2021;144:14410. doi: 10.16/j.ypmed.2020.106399
- World Health Organization. Accelerating the elimination of cervical cancer as a global public health problem. World Health Organization. 2019 [cited 2024 Feb 27]. Available from:https://apps.who.int/gb/ebwha/pdf_files/EB146/B146_9-en.pdf
- van Lier EA, Oomen PJ, Giesbers H, et al. Vaccinatiegraad en jaarverslag: Rijksvaccinatieprogramma Nederland 2021. Nederland: Rijksinstituut voor Volksgezondheid en Milieu; 2022 [cited 2024 Feb 27]. Available from: https://www.rivm.nl/bibliotheek/rapporten/2022-0017.pdf
- Aubin F, Pretet JL, Jacquard AC, et al. Human papillomavirus genotype distribution in external acuminata condylomata: a large French national study (EDiTH IV). Clin Infect Dis. 2008;47(5):610–615. doi: 10.1086/590560
- Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–814. doi: 10.1086/597071
- European Medicines Agency. Gardasil. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil
- European Medicines Agency. Gardasil 9. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/gardasil-9
- Brown DR, Joura EA, Yen GP, et al. Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine. 2021;39(16):2224–2236. doi: 10.1016/j.vaccine.2020.11.076
- Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis. 2009;199(7):936–944. doi: 10.1086/597309
- Phillips A, Patel C, Pillsbury A, et al. Safety of human papillomavirus vaccines: an updated review. Drug Saf. 2018;41(4):329–346. doi: 10.1007/s40264-017-0625-z
- Largeron N, Petry KU, Jacob J, et al. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017;17(1):85–98. doi: 10.1080/14737167.2016.1208087
- Tay SK, Hsu TY, Pavelyev A, et al. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis. BJOG. 2018;125(4):478–486. doi: 10.1111/1471-0528.15106
- Westra TA, Stirbu-Wagner I, Dorsman S, et al. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis. 2013;13(1):1–11. doi: 10.1186/1471-2334-13-75
- National Institute for Public Health and the Environment. Newsletter: Dutch population screening for cervical cancer 2022. 2022 [cited 2024 Feb 27]. Available from: https://www.rivm.nl/sites/default/files/2023-01/Newsletter%20Dutch%20population%20screening%20for%20cervical%20cancer%202022%20DEF2.pdf
- Jansen E, Naber SK, Aitken CA, et al. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study. BJOG. 2021;128(3):573–582. doi: 10.1111/1471-0528.16400
- Hakkaart-van Roijen L, van der Linden N, Bouwmans C, et al. Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg Zorginstituut Nederland. 2015 [cited 2024 Feb 27]. Available from: https://www.zorginstituutnederland.nl/binaries/zinl/documenten/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg.pdf
- Cody P, Tobe K, Abe M, et al. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study. BMC Infect Dis. 2021;21(1):1–13. doi: 10.1186/s12879–020–05632–0
- Daniels V, Prabhu VS, Palmer C, et al. Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. Hum Vaccin Immunother. 2021;17(7):1943–1951. doi: 10.1080/21645515.2020.1852870
- Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG. 2008;115(8). doi: 10.1111/j.1471-0528.2008.01743.x
- Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858–6867.
- Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(11):28–41.
- Elbasha EH, Dasbach EJ, Insinga RP. A multi-type HPV transmission model. Bull Math Biol. 2008;70(8). doi: 10.1007/s11538-008-9338-x
- National Institute for Public Health and the Environment. Cervical cancer population screening in the Netherlands: factsheet 2021. 2021 [cited 2024 Feb 27]. Available from: https://www.rivm.nl/sites/default/files/2022-03/013673%20Factsheet%20Cervical%20Cancer%20Screening.pdf
- Rijksinstituut voor Volksgezondheid en Milieu. monitor bevolkingsonderzoek baarmoederhalskanker 2018. 2019. Available from: https://www.rivm.nl/sites/default/files/2019-12/Monitor%20BMHK%202018.pdf
- United Nations Statistics Division. Demographic Yearbook – 2019. 2019. Available from: https://unstats.un.org/unsd/demographic-social/products/dyb/dyb_2019/
- Hethcote HW. An age-structured model for pertussis transmission. Math Biosci. 1997;145(2). doi: 10.1016/s0025-5564(97)00014-x
- de Graaf H, Wijsen C. Sexuele Gezondheid in Nederland 2017. 2017 [cited2024 Feb 27]. Available from: https://rutgers.nl/wp-content/uploads/2021/03/Seksuele-Gezondheid-in-Nederland-2017.pdf
- Garnett GP, Anderson RM. Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Philos Trans R Soc Lond B Biol Sci. 1993;342(1300). doi: 10.1098/rstb.1993.0143
- Mercer CH, Tanton C, Prah P, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the national surveys of sexual attitudes and lifestyles (natsal). Lancet. 2013;382(9907). doi: 10.1016/S0140-6736(13)62035-8
- Hanstede MM, Burger MJ, Timmermans A, et al. Regional and temporal variation in hysterectomy rates and surgical routes for benign diseases in the Netherlands. Acta Obstet Gynecol Scand. 2012;91(2):220–225. doi: 10.1111/j.1600-0412.2011.01309.x
- Ault KA, IISG F. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. The Lancet. 2007;369(9576):1861–1868. doi: 10.1016/S0140-6736(07)60852-6
- Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–1943. doi: 10.1056/NEJMoa061760
- Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–411. doi: 10.1056/NEJMoa0909537
- Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723. doi: 10.1056/NEJMoa1405044
- Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574). doi: 10.1016/S0140-6736(07)60777-6
- Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576–1585. doi: 10.1056/NEJMoa1010971
- Rijksinstituut voor Volksgezondheid en Milieu. Vaccinatiegraad en jaarverslag Rijksvaccinatieprogramma Nederland 2018 2019. Available from: https://www.rivm.nl/publicaties/vaccinatiegraad-en-jaarverslag-rijksvaccinatieprogramma-nederland-2018
- Medicijnkosten.nl. GARDASIL 9 INJSUSP WWSP 0,5ML. Available from: https://www.medicijnkosten.nl/medicijn?artikel=GARDASIL+9+INJSUSP+WWSP+0%2C5ML&id=fc25241a7318c7a927bd91e42edf846f
- Szende A, Janssen B, Cabases J, Editors. Self-reported population health: an international perspective based on EQ-5D [Internet]. Dordrecht (NL): Springer; 2014. PMID: 29787044.
- Luttjeboer J, Westra TA, Wilschut JC, et al. Cost–effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account. Vaccine. 2013;31(37):3922–3927. doi: 10.1016/j.vaccine.2013.06.044
- Qendri V, Bogaards JA, Berkhof J. Health and economic impact of a tender-based, sex-neutral human papillomavirus 16/18 vaccination program in the Netherlands. J Infect Dis. 2017;216(2):210–219. doi: 10.1093/infdis/jix272
- Ministry of Finance. 3.1 Article 1 public health 2022. Available from: https://www.rijksfinancien.nl/memorie-van-toelichting/2022/1SUPP/XVI/onderdeel/1276156
- Apter D, Wheeler CM, Paavonen J, et al. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015;22(4):361–373. doi: 10.1128/CVI.00591-14
- Gamerman D, Lopes HF. Markov Chain Monte Carlo: stochastic simulation for bayesian inference. Second ed. Chapman & Hall; 2006.
- Zwaap J, Knies S, van der Meijden C, et al. Kosteneffectiviteit in de praktijk Zorginstituut Nederland. 2015 [cited 2024 Feb 27]. Available from: https://www.zorginstituutnederland.nl/publicaties/rapport/2015/06/26/kosteneffectiviteit-in-de-praktijk
- Statista. Gross domestic product (GDP) per capita in the Netherlands from 1960 to 2021 2022. Available from: https://www.statista.com/statistics/530398/netherlands-gdp-per-capita/